RWE in Europe – An Analysis
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Background – This paper outlines findings from four roundtable discussions involving a number of stakeholders. They aimed to improve understanding of the use of real world evidence (RWE) across Europe. They focused on the development of a three-year roadmap for the increased incorporation of RWE, increasingly recognized as a valuable source of information for market access and reimbursement, in decision-making. Methods – The meetings involved participants from 12 European countries. Participants had significant knowledge of specialist disease areas and commissioning of care and prior experience in the field of RWE. All four meetings involved plenary sessions with opportunity for discussion and feedback from participants. Specific topics of interest included the role of RWE in licensing, commissioning, clinical and patients and outcomes in chronic disease, oncology and rare diseases. Results – We garnered significant insight into the current and future use of RWE across Europe, developing a three-year roadmap of initiatives for the enhanced use of RWE in decision-making. Four initiatives were seen to be the most important at this stage: actively engaging in early dialogue with payers on RWE needs; a consensus exercise on RWD/RWE in clinical decisions; developing a definition of Patient Reported and Patient Relevant Outcomes (PRO); and developing a model approach for the collection of PRO. Conclusions – The roundtable discussions generated a wealth of information around the current and future value of RWE across Europe. Significant work is required in the areas of data generation, interpretation and use to make its inclusion in commissioning and licensing based decision-making more mainstream.
Authors and Affiliations
Jennifer Gill, Panos Kanavos
Keywords
Related Articles
- EP ID EP326181
- DOI 10.7365/JHPOR.2017.2.1
- Views 79
- Downloads 0
Asthma boundaries in a social security perspective
ntroduction: Patients in Poland, including asthmatics are beneficiaries of social security system in case of severe disease exacerbation. Usually sick leave due to uncontrolled asthma is enough to get better and come bac...
The assessment of the impact of thrombocytopenia symptoms on the patients’ daily activities with the use of TSIDAV vignette
Objective: Assessment of the impact of thrombocytopenia symptoms on patients’ daily activities using vignettes. Methods: Vignettes were used to collect information from adult patients and children’s caregivers in order...
Cancer immunotherapy in second-line treatment of non-small cell lung cancer – is there a need to change the approach to the assessment of clinical benefits?
Background: The mechanism of action distinctive for immunotherapy leads to the specific pattern of tumour response, different form the one observed with cytotoxic therapy. To enable a complete assessment of immunotherape...
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...
RWE in Europe – An Analysis
Background – This paper outlines findings from four roundtable discussions involving a number of stakeholders. They aimed to improve understanding of the use of real world evidence (RWE) across Europe. They focused on th...